RPTX实时信号 | 通过Getagraph.com最大化利润

购买 109502 min ago

@ $7.51

发出时间: 13 Feb 2024 @ 22:30

回报率: -57.39%

上一信号: Feb 12 - 22:40

上一信号: 出售

回报率: -7.28 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:28):

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States...

Stats
今日成交量	14 037.00
平均成交量	130 898
市值	134.98M
EPS	$0 ( 2024-02-27 )
下一个收益日期	( $-0.100 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.0230 (0.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Segal Lloyd Mitchell	Sell	2 650	Common Shares
2024-04-01	Segal Lloyd Mitchell	Sell	2 491	Common Shares
2024-03-28	Forte Steve	Sell	825	Common Shares
2024-04-01	Forte Steve	Sell	789	Common Shares
2024-03-28	Zinda Michael	Sell	450	Common Shares

INSIDER POWER
69.42
Last 99 transactions
Buy: 4 214 315 \| Sell: 3 499 776

音量相关性

長: -0.08 (neutral)

短: -0.34 (neutral)

Signal:(45.417) Neutral

Repare Therapeutics Inc. 相关性

10 最正相关
AYTU	0.905
RPRX	0.905
RMCF	0.901
ALRS	0.897
HFWA	0.896
LBPS	0.894
TRIT	0.894
AMRB	0.892
RBB	0.89
BMRA	0.886

10 最负相关
DAKT	-0.913
CVT	-0.905
GBRG	-0.905
CMPO	-0.903
RAM	-0.899
DUOL	-0.897
VRIG	-0.894
BWMX	-0.893
BRACU	-0.882
HROW	-0.881

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Repare Therapeutics Inc. 相关性 - 货币/商品

-0.34
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.63
( weak negative )

0.64
( weak )

0.17
( neutral )

Repare Therapeutics Inc. 财务报表

Annual	2023
营收:	$51.13M
毛利润:	$49.18M (96.18 %)
EPS:	$-2.23

FY	2023
营收:	$51.13M
毛利润:	$49.18M (96.18 %)
EPS:	$-2.23

FY	2022
营收:	$131.83M
毛利润:	$127.65M (96.83 %)
EPS:	$-0.690

FY	2021
营收:	$7.60M
毛利润:	$7.60M (100.00 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Repare Therapeutics Inc.

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.